Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 NESH protein expression switches to the adverse effect of imatinib mesylate.

Literature DB >> 19383325

NESH protein expression switches to the adverse effect of imatinib mesylate.

Satoru Matsuda, Yasukatu Ichigotani, Naoko Okumura, Hitomi Yoshida, Yuka Kajiya, Yasuko Kitagishi, Naoki Shirafuji.

Abstract

Entities: Chemical Gene

Mesh：

Substances：

Year: 2008 PMID： 19383325 PMCID： PMC5527794 DOI： 10.1016/j.molonc.2008.03.003

Source DB: PubMed Journal: Mol Oncol ISSN： 1574-7891 Impact factor: 6.603

× No keyword cloud information.

16 in total

1. Forced expression of NESH suppresses motility and metastatic dissemination of malignant cells.

Authors: Yasukatu Ichigotani; Shouichi Yokozaki; Yoshihide Fukuda; Michinari Hamaguchi; Satoru Matsuda
Journal: Cancer Res Date: 2002-04-15 Impact factor: 12.701

2. Isolation and characterization of a novel human gene (NESH) which encodes a putative signaling molecule similar to e3B1 protein.

Authors: K Miyazaki; S Matsuda; Y Ichigotani; Y Takenouchi; K Hayashi; Y Fukuda; Y Nimura; M Hamaguchi
Journal: Biochim Biophys Acta Date: 2000-09-07

3. Development of multiple myeloma in a patient with chronic myeloid leukemia after treatment with imatinib mesylate.

Authors: Vassilia Garipidou; Sofia Vakalopoulou; Konstantinos Tziomalos
Journal: Oncologist Date: 2005 Jun-Jul

4. NESH protein expression switches to the adverse effect of imatinib mesylate.

Authors: Satoru Matsuda; Yasukatu Ichigotani; Naoko Okumura; Hitomi Yoshida; Yuka Kajiya; Yasuko Kitagishi; Naoki Shirafuji
Journal: Mol Oncol Date: 2008-03-20 Impact factor: 6.603

5. c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF.

Authors: R Plattner; L Kadlec; K A DeMali; A Kazlauskas; A M Pendergast
Journal: Genes Dev Date: 1999-09-15 Impact factor: 11.361

6. NESH (Abi-3) is present in the Abi/WAVE complex but does not promote c-Abl-mediated phosphorylation.

Authors: Noriko Hirao; Seiichi Sato; Tetsuya Gotoh; Masahiro Maruoka; Jun Suzuki; Satoru Matsuda; Tomoyuki Shishido; Katsuko Tani
Journal: FEBS Lett Date: 2006-11-07 Impact factor: 4.124

7. Abl-interactor-1, a novel SH3 protein binding to the carboxy-terminal portion of the Abl protein, suppresses v-abl transforming activity.

Authors: Y Shi; K Alin; S P Goff
Journal: Genes Dev Date: 1995-11-01 Impact factor: 11.361

8. Abi-2, a novel SH3-containing protein interacts with the c-Abl tyrosine kinase and modulates c-Abl transforming activity.

Authors: Z Dai; A M Pendergast
Journal: Genes Dev Date: 1995-11-01 Impact factor: 11.361

9. Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents.

Authors: Atanasio Pandiella; Xonia Carvajal-Vergara; Soraya Tabera; Gema Mateo; Norma Gutiérrez; Jesús F San Miguel
Journal: Br J Haematol Date: 2003-12 Impact factor: 6.998

NESH protein expression switches to the adverse effect of imatinib mesylate.

1. Forced expression of NESH suppresses motility and metastatic dissemination of malignant cells.

2. Isolation and characterization of a novel human gene (NESH) which encodes a putative signaling molecule similar to e3B1 protein.

3. Development of multiple myeloma in a patient with chronic myeloid leukemia after treatment with imatinib mesylate.

4. NESH protein expression switches to the adverse effect of imatinib mesylate.

5. c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF.

6. NESH (Abi-3) is present in the Abi/WAVE complex but does not promote c-Abl-mediated phosphorylation.

7. Abl-interactor-1, a novel SH3 protein binding to the carboxy-terminal portion of the Abl protein, suppresses v-abl transforming activity.

8. Abi-2, a novel SH3-containing protein interacts with the c-Abl tyrosine kinase and modulates c-Abl transforming activity.

9. Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents.

10. Down-regulation of WAVE3, a metastasis promoter gene, inhibits invasion and metastasis of breast cancer cells.

1. NESH protein expression switches to the adverse effect of imatinib mesylate.

2. Microglia express ABI3 in the brains of Alzheimer's disease and Nasu-Hakola disease.

Review 3. Against Lung Cancer Cells: To Be, or Not to Be, That Is the Problem.

4. The NESH/Abi-3-based WAVE2 complex is functionally distinct from the Abi-1-based WAVE2 complex.